AnalyticalThe role of lipoproteins in the transport and uptake of cyclosporine and dihydro-tacrolimus into HepG2 and JURKAT cell lines
References (28)
Cyclosporine, low density lipoprotein, and cholesterol
- et al.
Preperative and quantitative isolation of plasma lipoproteins: Rapid, single discontinuous density gradient ultracentrifugation in a vertical rotor
J Lipid Res
(1980) - et al.
Characterization of receptors for bombesin/gastrin-releasing peptide in human and murine cells
Methods Enzym
(1989) - et al.
Protein measurement with the Folin phenol reagent
J Biol Chem
(1951) - et al.
Cholesterol synthesis in cultured human peripheral lymphocytes. Influence of LDL, HDL cholesterol/phosphatidylcho line liposomes and complete serum
Biochim Biophys Acta
(1986) - et al.
Inhibition of T-cell activity by cyclosporin A
Scand J Immunol
(1981) - et al.
FK-506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK-506 in vitro
J Antibiot
(1987) Factors influencing the pharmacokinetics of cyclosporine in man
Ther Drug Monit
(1991)- et al.
Distribution and concentration of cyclosporin in human blood
J Clin Pathol
(1984) - Jusko WJ, Thomson AW, Fung J, et al. Consensus document: Therapeutic monitoring of Tacrolimus (Tacrolimus). Ther Drug...
Distribution and binding of cyclosporine in blood and tissues
Pharmacokinetics of FK 506: Preclinical and clinical studies
Interaction of cyclosporine A with human lipoproteins
J Pharm Pharmacol
Distribution of FK 506 in plasma lipoproteins in transplant patients
Cited by (20)
Cyclosporin a-induced dyslipidemia and LDL receptors
2018, The Molecular Nutrition of FatsCan 100 papers over 50 years tell the story of a scientific journal?
2017, Clinical BiochemistryCitation Excerpt :Establishment of pediatric reference intervals [43] Mechanistic studies on drug uptake [44] Validation of reference methods [45]
Cholesteryl ester transfer protein facilitates the movement of water-insoluble drugs between lipoproteins: A novel biological function for a well-characterized lipid transfer protein
2002, Biochemical PharmacologyCitation Excerpt :Several investigators have reported decreased pharmacological effects of CSA with hyperlipidemia (particularly in hypertriglyceridemia) [37,38], and increased toxic effects of CSA with hypolipidemia (particularly hypocholesterolemia) [39]. Investigations have demonstrated that the cellular uptake of CSA is mediated through HDL [40] and LDL receptors [41], although recent work has shown that lipoproteins may not serve as a vehicle for the cellular uptake of CSA into hepatic-derived cells [42]. However, Lemaire et al.[43] have suggested that the availability of the drug to tissue and, hence, its pharmacological (or toxic) effects may depend upon the lipoprotein to which the drug is bound.
Effects of lipoproteins on cyclosporine A toxicity and uptake in LLC-PK<inf>1</inf> pig kidney cells
2001, Journal of Pharmaceutical SciencesCitation Excerpt :The cellular uptake of CSA may be mediated through hepatic HDL21 and LDL receptors.22 However, recent work by Rifai et al. has shown that despite significant association of CSA with HDL and LDL, these lipoproteins may not serve as vehicles for the cellular uptake of CSA into hepatic‐derived cells.23 Taken together, these studies provide preliminary evidence that plasma lipoprotein association may impact the toxicity of CSA.